Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation.

Citation: Curreli F, Ahmed S, Benedict Victor SM, Iusupov IR, Belov DS, Markov PO, Kurkin AV, Altieri A, Debnath AK.: Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation. J Med Chem, Volume 63 (4), 2020
Authors: Ahmed S, Altieri A, Belov DS, Benedict Victor SM, Curreli F, Debnath AK., Iusupov IR, Kurkin AV, Markov PO
Journal: J Med Chem
Year: 2020
DOI: 10.1021/acs.jmedchem.9b02149
PubMed: 32031803
Machine-readable: REST API RDF

Publication